Going anti-Viral
Introducing Going anti-Viral, the podcast of the IAS–USA, a professional continuing medical education organization focused on HIV and other viral diseases. I’m Dr Michael Saag, professor emeritus of medicine and infectious diseases at the University of Alabama at Birmingham and volunteer member of the IAS–USA Board of Directors.
Join us as we interview experts in viral medicine about their area of specialty and current developments in the field. Other episodes are drawn from the IAS-USA vast catalogue of panel discussions, Dialogues, and various meetings and conferences.
Going anti-Viral is a podcast series for clinicians, produced by the International Antiviral Society–USA. The IAS–USA is a not-for-profit professional organization committed to improving the treatment, care, and quality of life for people with or at risk for HIV or other viral infections and their complications through balanced education and information. This podcast is intended as a clinical source of information for specialists in this field, but we hope anyone listening will enjoy learning more about the state of modern medicine around viral infections and their consequences.
Going anti-Viral
Next-Gen HIV Prevention and Treatment – Dr Judith Currier
In episode 49 of Going anti-Viral, Dr Judith Currier joins host Dr Michael Saag to discuss Next-Gen HIV Prevention and Treatment. Dr Currier is a Professor of Medicine at UCLA and has more than 25 years of experience in the design, implementation, conduct, and analysis of clinical trials to optimize antiretroviral management of HIV and related complications. Dr Currier and Dr Saag provide an overview of why new antiretroviral drugs are needed and discuss the successful return on investment in biomedical research. They also provide a detailed review of long-acting antiretroviral drugs and discuss the state of current research for new options, including a discussion of lenacapavir. Finally, they share their concerns for what is at stake if attempts to cut the federal research budget are successful and the disruption it will bring to the progress that has been made in HIV care and other viral diseases.
0:00 – Introduction
1:20 – Overview of why new antiretroviral drugs are needed
2:57 – The return on investment in biomedical research
3:52 – Overview of the need for long-acting antiretroviral drugs and options available
8:23 – Review of the current research and prospects for new long-acting therapies
12:59– Discussion of lenacapavir and the potential benefits for prevention and treatment
14:21 – Summary of other drugs on the horizon that may be potential treatments
18:39 – Overview of the different methods for delivery of drugs
21:11 – Impact of potential budget cuts on HIV research, on people with HIV, and on other viral diseases
__________________________________________________
Produced by IAS-USA, Going anti–Viral is a podcast for clinicians involved in research and care in HIV, its complications, and other viral infections. This podcast is intended as a technical source of information for specialists in this field, but anyone listening will enjoy learning more about the state of modern medicine around viral infections.
Going anti-Viral’s host is Dr Michael Saag, a physician, prominent HIV researcher at the University of Alabama at Birmingham, and volunteer IAS–USA board member. In most episodes, Dr Saag interviews an expert in infectious diseases or emerging pandemics about their area of specialty and current developments in the field. Other episodes are drawn from the IAS–USA vast catalogue of panel discussions, Dialogues, and other audio from various meetings and conferences.
Email podcast@iasusa.org to send feedback, show suggestions, or questions to be answered on a later episode.
Follow Going anti-Viral on:
Apple Podcasts
YouTube
X
Facebook
Instagram
...